多 (ADP-ribose) 聚合酶1和神经退行性疾病:过去,现在和未来
Meng-Ling Hu1, Yi-Ru Pan1, Yuan-Yuan Yong1
1Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China.
Ageing research reviews
|September 27, 2023
概括
聚 (ADP-ribose) 聚合酶1 (PARP1) 在神经退行性疾病中起着双重作用,在早期有助于修复,但当过度激活后会使情况恶化. 抑制PARP1过度激活是一种有前途的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多 (ADP-ribose) 聚合酶1 (PARP1) 对于DNA损伤的修复至关重要.
- 神经退行性疾病涉及与DNA损伤相关的渐进性神经元损失.
- 在疾病进展过程中,PARP1的激活从有益转变为有害.
研究的目的:
- 审查PARP1在神经退行性疾病中的复杂作用.
- 为了突出在疾病病理学中PARP1过度激活.
- 探索涉及PARP1抑制的治疗策略.
主要方法:
- 综合和综述文学综合和综述.
- 对PARP1参与蛋白质聚合,自,线粒体,神经炎症和BBB损伤的分析.
- 评估PARP1抑制剂的应用,局限性和协同潜力.
主要成果:
- 过度激活PARP1会通过各种病理途径加剧神经退行.
- PARP1 抑制剂显示出治疗前景,但面临着特异性和临床转化等挑战.
- 研究了将PARP1抑制剂与其他药物结合的协同策略.
结论:
- 准PARP1过度激活是神经退行性疾病的关键治疗途径.
- 未来的研究应该专注于疾病特异性的PARP1作用,组合疗法和个性化医学.
- 为推进神经退行性疾病中PARP1抑制剂的利用提供了战略建议.
相关概念视频
Parkinson's Disease: Overview
590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
Biosynthesis of Nucleic Acids
67
Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
67
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Proofreading
6.3K
Synthesis of new DNA molecules is carried out by the enzyme DNA polymerase, which adds nucleotides on the daughter strand complementary to the template DNA strand. DNA polymerase has a higher affinity to add the correct base and ensures fidelity during DNA replication. Furthermore, it exhibits proofreading activity during replication, using an exonuclease domain that cuts off incorrect nucleotides from the nascent DNA strand.
Errors During Replication are Corrected by the DNA Polymerase...
Errors During Replication are Corrected by the DNA Polymerase...
6.3K
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K


